MAPT and Alzheimer disease: However, there have been numerous advancements towards determining suitable blood-based biomarkers for the identification of individuals presenting with preclinical AD (i.e., plasma Aβ1–42/Aβ1–40 ratio and Tau phosphorylated at residues 181, 217, or 231).